BIOMARIN PHARMACEUTICAL INC's ticker is and the CUSIP is 09061GAH4. A total of 55 filers reported holding BIOMARIN PHARMACEUTICAL INC in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $333,000 | +2.5% | 310,000 | 0.0% | 0.00% | – |
| Q3 2020 | $325,000 | -97.0% | 310,000 | -96.6% | 0.00% | -100.0% |
| Q2 2020 | $10,999,000 | +949.5% | 9,000,000 | +800.0% | 0.00% | – |
| Q1 2020 | $1,048,000 | -0.8% | 1,000,000 | 0.0% | 0.00% | – |
| Q4 2019 | $1,056,000 | -2.3% | 1,000,000 | -9.1% | 0.00% | – |
| Q3 2019 | $1,081,000 | -38.8% | 1,100,000 | -35.3% | 0.00% | – |
| Q2 2019 | $1,765,000 | +1.3% | 1,700,000 | -0.2% | 0.00% | – |
| Q1 2019 | $1,742,000 | +39.0% | 1,703,000 | +35.2% | 0.00% | – |
| Q4 2018 | $1,253,000 | -87.6% | 1,260,000 | -86.7% | 0.00% | -100.0% |
| Q3 2018 | $10,125,000 | -3.6% | 9,500,000 | -8.7% | 0.00% | 0.0% |
| Q2 2018 | $10,506,000 | -16.2% | 10,400,000 | -22.1% | 0.00% | 0.0% |
| Q1 2018 | $12,532,000 | -19.1% | 13,350,000 | -14.1% | 0.00% | -50.0% |
| Q4 2017 | $15,492,000 | +40.3% | 15,550,000 | +42.7% | 0.00% | +100.0% |
| Q3 2017 | $11,043,000 | – | 10,900,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SHENKMAN CAPITAL MANAGEMENT INC | 16,298,000 | $15,340,000 | 1.64% |
| ZAZOVE ASSOCIATES LLC | 25,540,000 | $24,103,000 | 1.55% |
| PIER 88 INVESTMENT PARTNERS LLC | 3,030,000 | $2,844,000 | 1.36% |
| Jabre Capital Partners S.A. | 5,500,000 | $5,184,000 | 1.12% |
| Sonora Investment Management, LLC | 7,100,000 | $6,681,214,000 | 1.06% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 43,256,000 | $40,793,000 | 0.80% |
| Opera Trading Capital | 10,000,000 | $9,370,000 | 0.72% |
| AQR Arbitrage LLC | 52,575,000 | $49,486,000 | 0.57% |
| Neuberger Berman Group LLC | 5,000,000 | $469,375,000 | 0.54% |
| CQS Cayman LP | 12,000,000 | $11,322,000 | 0.52% |